The State of Personalized/Precision Medicine

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Personalized/Precision medicine is a field of medicine that uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat diseases. In cancer, personalized medicine uses specific information about an individual to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis.

The state of personalized/precision medicines market research report covers current and future challenges for the development and launch of these medicines.

Key Findings

  • More randomized controlled prospective clinical trials are needed to identify proven diagnostic tests that will be reimbursed alongside the use of personalized medicine.
  • The biggest challenge in developing personalized medicine is meeting the regulatory standards of the FDA and EMA.
  • Personalized medicine’s sole purpose is to provide treatments that better fit specific patient populations, rather than providing inconsistent results in a broader patient population.
  • Pricing and reimbursement are among the biggest challenges in personalized medicine, as for the treatment to be available for patients, the diagnostic must also be reimbursed.

For more insights on key findings, download a free report sample

Personalized/Precision Medicines Market Drivers

Some of the market drivers of the personalized/precision medicines market include:

  • Rising aging population
  • Increased emphasis on cost-effective healthcare
  • Availability of new technologies
  • Significant investments in personalized medicine
  • Increased focus on value-based healthcare models
  • Focus on preventative medicine
  • The popularity of targeted therapies
  • Evolving regulations
  • Increased biomarker and targeted therapy R&D

The global population is aging due to improvements in life expectancy because of better healthcare, medical advances in treating diseases, and improved sanitation. However, the overall level of health has not improved, and the burden of disease has moved from tackling infectious diseases to managing long-term conditions such as diabetes, cardiovascular diseases, and cancer.

Advantages of Personalized Medicine

Some of the advantages that personalized medicines can bring to patients are listed below:

  • More efficient selection of the right treatment path
  • Cost-effectiveness for the healthcare system
  • Better optimal dosing regimens
  • Enhancement of quality of life
  • Minimization of adverse drug reactions
  • Increased prevention and earlier intervention possibilities
  • Increased treatment options

The main advantage of personalized medicine is that it allows more efficient selection of the right treatment path. By enabling each patient to receive earlier risk assessment and a more efficacious tailored treatment, personalized medicine is expected to transform healthcare.

Key Therapy Areas in the Personalized/Precision Medicines Market

The key therapy areas in the personalized/precision medicines market are oncology, respiratory, hematology, infectious diseases, ophthalmology, metabolic, central nervous system, cardiovascular, gastrointestinal, musculoskeletal & rheumatology, and dermatology. Oncology is the largest segment in the personalized/precision medicine market followed by respiratory and hematology.

Personalized/Precision Medicines Market Analysis by Therapy Areas

Personalized/Precision Medicines Market Analysis by Therapy Areas

For more therapy area insights, download a free report sample

Key Players in the Personalized/Precision Medicines Market

Some of the key players in the personalized/precision medicines market are 23andMe, Adaptive Biotechnologies, Ambry Genetics Corp, Astellas, AstraZeneca, Baxalta, BeiGene, Berg Health, BrainStorm Cell Therapeutics, Bristol-Myers Squibb, Catabasis, Clovis Oncology, Denovo Biopharma, Eli Lilly, Foundation Medicine, GenSight Biologics, and IgDraSol.

Personalized/Precision Medicines Market Report Overview

Key Therapy Areas Oncology, Respiratory, Hematology, Infectious Diseases, Ophthalmology, Metabolic, Central Nervous System, Cardiovascular, Gastrointestinal, Musculoskeletal & Rheumatology, and Dermatology
Key Players 23andMe, Adaptive Biotechnologies, Ambry Genetics Corp, Astellas, AstraZeneca, Baxalta, BeiGene, Berg Health, BrainStorm Cell Therapeutics, Bristol-Myers Squibb, Catabasis, Clovis Oncology, Denovo Biopharma, Eli Lilly, Foundation Medicine, GenSight Biologics, and IgDraSol


GlobalData’s The State of Personalized/Precision Medicine combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at personalized and precision medicine in the US, Europe, and Asia.

Components of the report include:

  • Definition of Personalized/Precision Medicine—Key attributes of personalized/precision medicine, examining and contrasting definitions by regulatory bodies and KOL respondents.
  • Personalized Medicine—Impact on Healthcare—Key factors to impacting healthcare for patients and stakeholders providing respondent mix by region and organization size.
  • Marketed products—Detailed information is provided for key personalized/precision medicines, including case studies for marketed oncology and rare disease therapeutics.
  • Pipeline products—The diverse Phase III pipeline is presented, including detailed information on the key candidate’s mechanism of action and clinical trial parameters.
  • Investment in Personalized Medicine—Investment in personalized medicine by indication and clinical trial design and approaches are presented, with case studies for three ongoing oncology trials being considered.
  • Market Opportunities and Challenges—Key areas of opportunity and roadblocks in developing, launching, and gaining reimbursement are analyzed by geography, company size, and seniority level.
  • Emerging Trends—Critical new trends, including the use of advanced digital technologies, are examined.

Reasons to Buy

  • Develop business strategies by understanding the global trends shaping and driving the personalized/precision medicines market
  • Formulate effective sales and marketing strategies by understanding the competitive landscape of various competitors in a niche therapeutic space.
  • Identify areas of unmet need within the personalized/precision market to help drive research and development towards future market opportunities.
  • Gain insights to help plan and design your clinical trials.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
  • Identify key funding and partnership strategies.

Adaptive Biotechnologies
Ambry Genetics Corp
Berg Health
BrainStorm Cell Therapeutics
Bristol-Myers Squibb
Clovis Oncology
Denovo Biopharma
Eli Lilly
Foundation Medicine
GenSight Biologics
Konica Minolta
Loxo Oncology
Merck & Co.
Nebula Genomics
Precision Biosciences
Revolution Medicines
Rhythm Pharmaceuticals
Sutro Biopharma

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1 Table of Concents

1.2 Abbreviations

1.3 Related Reports

1.4 Upcoming Related Reports

2. Executive Summary

2.1 Key Findings

2.2 KOL and Payer Insights

3. Overview of Personalized/Precision Medicine

3.1 Definition

3.2 Definition of Personalized/Precision Medicine

3.3 KOL and Payer Perspecive

3.4 Key Attributes of Personalized Medicine Therapy

3.5 Types of Biomarkers and Diagnostics

4. Impact of Personalized Medicine on Healthcare

4.1 Personalized Medicine – Impact on Healthcare – Patients

4.2 Advantages of Personalized Medicine – Patients

4.3 Role of Personalized Medicine in Clinical Unmet Needs

4.4 Personalized Medicine – Impact on Healthcare – Drug Developers’ Perspective

4.5 Advantages of Personalized Medicine to Drug Developers

4.6 Personalized Medicine – Impact on Healthcare – Health System

5. Key Marketed Products

5.1 Leading Marketed Products

5.2 Pfizer’s Xalkori

5.3 Sarepta’s Exondys 51

5.4 Roche/Genentech’s Tarceva

5.5 Vertex’s Symdeko

5.6 AstraZeneca’s Imfinzi

5.7 Roche’s Herceptin

5.8 AstraZeneca’s Lynparza

5.9 Merck & Co.’s Keytruda

5.10 Novartis’ Tafinlar + Mekinist

6. Pipeline Products

6.1 Personalized Medicine Pipeline Candidates

6.2 BeiGene’s Pamiparib

6.3 Rhythm’s Setmelanotide

6.4 Denovo’s Enzastaurin

6.5 Roche/Genentech’s Ipatasertib

6.6 GenSight’s Lenadogene Nolparvovec

6.7 Catabasis’ Edasalonexent

6.8 Marinus’ Ganaxolone

6.9 Kiadis’ ATIR-101

6.10 Retrophin’s Fosmetpantotenate

6.11 BrainStorm’s NurOwn

6.12 AstraZeneca’s Savolitinib

7. Investment in Personalized Medicine

7.1 Involvement with Personalized Medicine

7.2 Investment in Personalized Medicine

7.3 Clinical Trial Activity

7.4 Personalized Medicine Clinical Trial Design

7.5 NCI-MATCH Clinical Trial

7.6 NAVIGATE Clinical Trial

7.7 BATTLE‐2 Clinical Trial

8. Deal-Making Landscape

8.1 Personalized Medicine Deals

9. Market Opportunities and Challenges

9.1 Market Drivers

9.2 Market Barriers

9.3 Major Challenges in Developing Personalized Medicine

9.4 Major Challenges in Launching Personalized Medicine

9.5 Challenges in Transitioning Personalized Medicine from Bench to Bedside

9.6 Major Challenges in Developing and Launching Personalized Medicine

10. Pricing, Reimbursement, and Regulatory Strategy

10.1 Personalized Medicine Regulation and Reimbursement

10.2 Personalized Medicine Regulation in the US

10.3 Obama’s Precision Medicine Initiative

10.4 Pricing and Reimbursement in the US

10.5 Personalized Medicine Regulation in the EU

10.6 Personalized Medicine Reimbursement in the EU

10.7 Personalized Medicine Regulation and Reimbursement in Japan

10.8 Personalized Medicine Regulation and Reimbursement in China

10.9 Currently Marketed Personalized Medicine Products

11. Personalized Medicine – Emerging Trends

11.1 Personalized Medicine and AI

11.2 Personalized Medicine and AI – Case Study

11.3 Personalized Medicine and Big Data

11.4 Personalized Medicine and Big Data – Case Study

11.5 Personalized Medicine and Blockchain

11.6 Personalized Medicine and Blockchain – Case Study

11.7 Personalized Medicine and Digital Therapeutics

11.8 Personalized Medicine and Digital Therapeutics – Case Study

12. Summary of Key Findings

12.1 Market Outlook

12.2 Recommendations

12.3 Future Implications for Personalized Medicine

13. Appendix

13.1 Personalized Medicine Sources

13.2 Methodology

13.3 Study Design

13.4 Primary Research – Online Survey

13.5 Primary Research – KOLs and Payers

13.6 About the Authors

13.7 About GlobalData

13.8 Contact Us

13.9 Disclaimer

Frequently asked questions

The State of Personalized/Precision Medicine thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

The State of Personalized/Precision Medicine was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at The State of Personalized/Precision Medicine in real time.

  • Access a live The State of Personalized/Precision Medicine dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.